Medical/Pharmaceuticals

Innovative strides in medical-grade TPUs: ICP DAS-BMP to introduce groundbreaking solutions at CMEF and Medtec Japan

HSINCHU, March 27, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), Asia's leading medical TPU (thermoplastic polyurethane) manufacturer and supplier, will exhibit at the International Component Manufacturing and Design Show (ICMD, part of CMEF) and Medtec Japan inApril 2024. The company w...

2024-03-27 09:20 587

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...

2024-03-27 08:00 497

Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology

SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Raul...

2024-03-27 06:00 212

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...

2024-03-27 05:59 369

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by theChina's NMPA and granted priority review. * Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of t...

2024-03-27 01:16 548

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

EPLive 2024 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on co...

2024-03-26 23:58 329

Datasea Enters into 5G AI Multimodal Communication Cooperation Agreement Expected to Expand its China 5G Services Revenue

The Agreement with an Estimated Value of $30 Million Supports its Revenue Guidance of$86 Million, a 1,128% Year-Over-Year Increase for its Full Fiscal Year BEIJING, March 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative ...

2024-03-26 22:00 763

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...

2024-03-26 21:53 904

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release of the report "A White Paper To Understand The Market Structure Of Pediatric Pertussis Hexavalent and Combination Vaccines

2024-03-26 21:00 685

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...

2024-03-26 21:00 572

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors * Interim results from an ongoing Phase 1a study in healthy male volunteers will ...

2024-03-26 20:00 573

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

* MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events * Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of t...

2024-03-26 19:00 725

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...

2024-03-26 09:57 912

Scivita Medical Expands Collaboration with Boston Scientific

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.

2024-03-26 09:30 1010

BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167

SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...

2024-03-26 08:30 906

Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction

GEMBLOUX, Belgium, March 25, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control ("FANC"), auth...

2024-03-26 08:00 659

Mom Favorite Brand Momcozy Showcases Cutting-Edge Products at Medtrade 2024

NEW YORK, March 25, 2024 /PRNewswire/ -- Medtrade 2024 attendees looking for mom-centric products now have a new option on the Expo Floor,Momcozy . The mom-oriented, global brand is dedicated to provid...

2024-03-25 23:00 889

Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million

Steps up R&D investment Focuses on precision medicine and intelligent testing sectors HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year...

2024-03-25 22:54 1433

GenieMD Awarded Frost & Sullivan's 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions Through Its Unified Virtual Care Platform

GenieMD offers a comprehensive virtual care platform, integrating telehealth, remote patient monitoring, chronic care management, and AI-driven insights to impact the treatment and management of chronic diseases. SAN ANTONIO, March 25, 2024 /PRNewswire/ -- Frost & Sullivan recently researched th...

2024-03-25 22:31 1153

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

* Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 * Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022 * Total number of integrated projects increased to 143 * 50 new integrated projects signed in 2023 * Number of Phase...

2024-03-25 21:39 1703
12345 ... 573

Week's Top Stories